Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2022

May 12, 2022

SELL
$4.92 - $6.66 $109,224 - $147,852
-22,200 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$5.81 - $9.73 $66,234 - $110,922
11,400 Added 105.56%
22,200 $3,000
Q3 2021

Nov 10, 2021

BUY
$7.43 - $13.86 $80,244 - $149,688
10,800 New
10,800 $13,000

Others Institutions Holding ENLV

About Enlivex Therapeutics Ltd.


  • Ticker ENLV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 18,403,200
  • Market Cap $28.9M
  • Description
  • Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2...
More about ENLV
Track This Portfolio

Track Hap Trading, LLC Portfolio

Follow Hap Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Hap Trading, LLC with notifications on news.